Cardiovascular, metabolic and kidney disease: crosscutting science and best practice Are you involved with patients who have multimorbidity? This 1-day conference, held on 1 July 2019, will look at updates in multimorbidity and the clustering of common diseases in patients.
Evoking discussion and dialogue on ways to improve the health of these patients, the conference offers a packed programme full of interactive sessions and take-home messages for direct use on the ward.
Topics covered will look at: the latest insights from industry regarding the treatment of inflammation and fibrosis; how digital health and AI are driving research on delivering personalised medicine to patients; the epidemiology of multimorbidity in vascular disease.
Hurry! Book by 20 May to receive your early-bird discount.http://www.rcplondon.ac.uk/Cardiometabolic2019
This unique conference to be held at the RCP aims to stimulate discussion and ideas in addressing multi-morbidity and clustering of diseases which are a major problem for health service providers. It straddles all 5 related specialties in Division 2 of the NIHR CRN portfolio, namely cardiovascular disease, stroke, diabetes, metabolic disease and nephrology. There is a need for greater integration of clinical and basic science research and pathogenetic understanding between these disease clusters, with shared treatments developed to address common pathways. The conference will be of value to clinicians, scientists and other members of the multi-professional team, as well as Pharma representatives. Please consider attending.
Cardiovascular, metabolic and kidney disease: crosscutting science and best practice in multi-morbidity
Monday 1 July 2019
Royal College of Physicians, 11 St Andrews Place, Regent’s Park, London NW1 4LE
Programme organiser: Professor Philip Kalra, Renal Association
|
09.00 |
Registration and coffee |
|
09.25 |
Welcome and opening remarks
|
|
Session 1: The challenges from a point of care perspective |
|
|
09.30 |
Multi-morbidity at the coal face Professor Jackie Taylor, Royal College of Physicians and Surgeons of Glasgow
|
|
Session 2: Epidemiology and health inequalities in the multi-morbid population Chair: Professor John Wilding, University of Liverpool |
|
|
10.00 |
Epidemiology of multi-morbidity in the UK Dr Dorothea Nitsch, Royal Free London NHS Foundation Trust |
|
10.20 |
The healthcare providers’ perspective: current and future policy Professor Stephen Powis, NHS England |
|
10.40 |
The funder’s perspective: multi-morbidity and translating basic science into the best clinical trials Professor Paul Elliott, Imperial College London |
|
11.00
11.10 |
Q&A
Coffee |
|
Session 3: Accelerating research using current data and sample resources Chair: Professor Tom Robinson, University of Leicester |
|
|
11.30 |
Data sets: NHS digital, UK Renal Registry, NICOR, Stroke Registry and Diabetes National Audit CPRD Dr Fergus Caskey, University of Bristol |
|
11.50 |
Research networks and existing cohorts Professor David Wheeler, University College London |
|
12.10 |
Biomarkers Professor Maarten Taal, University of Nottingham |
|
12.30 |
Lunch |
|
Session 4: Underpinning scientific development and methodological issues Chair: Professor Paul Cockwell, University Hospitals Birmingham |
|
|
13.30 |
Omics potential Professor Desmond Johnston, Imperial College Healthcare |
|
13.50 |
Imaging potential Professor Sue Francis, University of Nottingham |
|
14.10 |
Devices and telemonitoring Professor Martin Cowie, Imperial College London |
|
Session 5: Current and future industry plans for multi-morbidity research Chair: Dr Claire Sharpe, King’s College London |
|
|
14.30 |
Improving multi-morbidity with newer anti-diabetic therapies Professor John McMurray, University of Glasgow |
|
14.50 |
Medicine development Tim Johnson, UCB and Professor Robert Unwin, AstraZeneca |
|
15.20 |
Tea |
|
Session 6: UK clinical platform for multi-morbidity research Chair: Professor John Feehally, University of Leicester and Professor Simon Heller, University of Sheffield |
|
|
15.50 |
Panel session TBC |
|
16.40 |
Proposed way forward Professor Philip Kalra, Renal Association |
|
16.55
17.00 |
Closing remarks Professor Philip Kalra, Renal Association and Sandra Currie, Kidney Research UK
Close of conference |
